David Ross Camidge, MD PhD

David Ross Camidge, MD, PhD

University of Colorado Cancer Center

Scientific and Clinical Advisors

Following a PhD in Molecular Biology at the Medical Research Council’s Laboratory of Molecular Biology at Cambridge University, UK, Dr Camidge completed his medical training at Oxford University, UK. He then became the first person to double train in Medical Oncology and Clinical Pharmacology in the UK, before joining the University of Colorado, USA from October 2005.

Dr Camidge’s main areas of clinical and research interest are thoracic malignancies and developmental therapeutics. The discoveries he and his team have made have changed the standard of care for the treatment of lung cancer multiple times. He has authored over 200 academic publications, including in the Journal of Thoracic Oncology, Journal of Clinical Oncology, Lancet Oncology, and New England Journal of Medicine. He has presented his work at numerous national and international meetings. In 2012 he received the Bonnie J. Addario International Lectureship Award as a ‘Luminary in the quest to eradicate lung cancer’.

In 2013 he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today’. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession’. In 2016, the Lung Cancer Foundation presented him with the Breath Away From The Cure Award describing him as ‘Simply one of the best in treating lung cancer today’.

In 2017 and 2018, he was internationally recognized as a highly cited researcher ranked in the top 1% of all of Clinical Medicine by Clarivate Analytics Web of Science. He is also the National Medical Director of the Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC), a member of the VIA Oncology Lung Cancer Pathways Committee and a past-member of the National Comprehensive Cancer Network Lung Cancer Committee.